NASDAQ · Biotechnology

Gamida Cell Ltd. (GMDA) Stock

$0.03 +0.00% NASDAQ: GMDA Healthcare

Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions.

Valuation

MetricValue
Price$0.03
Market Cap$4.34M
P/E Ratio-0.08
P/B Ratio-1.65
P/S Ratio2.43
EPS (TTM)$-0.57
52-Week High$0.04
52-Week Low$0.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE2100.00%
ROA-61.65%
ROCE-94.87%
Gross Margin-94.96%
Operating Margin-3650.00%
Net Margin-3150.00%
Debt/Equity-28.13
Current Ratio2.16

Annual Financials (USD)

Metric20192020202120222023
Revenue$0$0$0$0$2.0M
Operating Profit$-48.0M$-62.0M$-87.0M$75.0M$-73.0M
Net Profit$-34.0M$-76.0M$-92.0M$-154.0M$-63.0M
EPS$-1.16$-1.75$-1.56$-2.42$-0.57
Op Margin————-4094.1%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$69.0M$155.0M$149.0M$125.0M$102.0M
Total Liabilities$34.0M$57.0M$105.0M$133.0M$105.0M
Cash$42.0M$127.0M$56.0M$65.0M$47.0M
Borrowings$6.0M$8.0M$80.0M$104.0M$83.0M

Latest News

Why a 15% Yield on Blue Chip Stocks Worries Even Income Investors 24/7 Wall St. · Jul 26, 2026 Amazon marked down its 72-hour emergency kit just in time for storm season TheStreet · Jul 26, 2026 Honduran ex-president returns home after Trump pardon AFP · Jul 26, 2026 Yardeni asks: Which Inflation Rate Is Warsh Targeting? Investing.com · Jul 26, 2026 Dividend ETFs vs. Bond ETFs: Here's Which One Makes More Sense for Income Investors in This Market Motley Fool · Jul 26, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-38.0M$-49.0M$-82.0M$-70.0M$-79.0M
Investing Cash Flow$1.0M$-10.0M$-76.0M$28.0M$-2.0M
Financing Cash Flow$-1.0M$1.0M$1.0M$0$0
Net Cash Flow$2.0M$85.0M$-71.0M$9.0M$-18.0M
Free Cash Flow$-41.0M$-60.0M$-97.0M$-77.0M$-80.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.76
FCF Yield-1849.10%
Quick Ratio2.09
Interest Coverage-9.63
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APTOAptose Biosciences Inc. $1.71 +100.00% -0.16 $4.36M 0.00%
BCELAtreca, Inc. $0.09 -1.32% -0.04 $3.57M 0.00%
CYTOAltamira Therapeutics Ltd. $0.30 +100.00% -0.02 $1.13M 0.00%
GRTSGritstone bio, Inc. $0.03 -31.78% -0.03 $3.80M 0.00%
HILSHillstream BioPharma, Inc. $0.24 +5.66% -0.66 $4.17M 0.00%

About Gamida Cell Ltd.

Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.

Gamida Cell Ltd. is headquartered in IL.

Gamida Cell Ltd. (GMDA) stock trades at $0.03 with a market capitalization of $4.34M. The stock is valued at a price-to-earnings (P/E) ratio of -0.08, price-to-book of -1.65, price-to-sales of 2.43. Over the past 52 weeks the stock has ranged between $0.03 and $0.04, and currently trades 25.0% below its 52-week high.

On profitability, Gamida Cell Ltd. generates a return on equity (ROE) of 2100.00% — well above the market average, a sign of a high-quality business, return on capital employed of -94.87%, an operating margin of -3650.00%, a net profit margin of -3150.00%.

Official website: www.gamida-cell.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides